budesonide oral suspension

DRUG2 trials

Sponsors

Shire, Mayo Clinic

Conditions

Eosinophilic Esophagitis (EoE)

Early Phase 1

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

Enrolling by invitationNCT07358234

Mayo ClinicEosinophilic Esophagitis (EoE)

Start: 2026-02-04End: 2027-12-01Target: 60Updated: 2026-05-04

Phase 3

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

TerminatedNCT03245840

ShireEosinophilic Esophagitis (EoE)

Start: 2017-10-05End: 2022-04-26Updated: 2025-02-19

Related Papers

Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study

Clinical Gastroenterology and Hepatology2025-02-134 citations

Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis.

2024-12-232 citations

Effect of Esophageal Dilation History on Efficacy Outcomes in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension

The American Journal of Gastroenterology2024-11-123 citations

Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials

Alimentary Pharmacology & Therapeutics2023-03-0816 citations